Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral Irinotecan tablet product developed by Solural Pharma in combination therapy with oral capicitabine tablet in adult patients with solid tumors.
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
firstname.lastname@example.org for more information about available positions.